d’Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 28 févr 2005;165(4):416‑23. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/15738371
Costagliola D, Potard V, Duvivier C, Pradier C, Dupont C, Salmon D, et al. Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. Antivir Ther. 2005;10(4):563‑73. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/16038483
Girardi E, Sabin CA, d’Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 15 déc 2005;41(12):1772‑82. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/16288403
Grabar S, Le Moing V, Goujard C, Egger M, Leport C, Kazatchkine MD, et al. Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr. 1 juill 2005;39(3):284‑92. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/15980687
May M, Porter K, Sterne JAC, Royston P, Egger M. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol. oct 2005;58(10):1033‑41. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/16168349
Sabin C, Antiretroviral Therapy (ART) Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS. 18 nov 2005;19(17):1995‑2000. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/16260906
